Gene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News
Mason Two Crow, 22, first came to the Retina Foundation in 2003 with a diagnosis of X-linked retinoschisis, a rare genetic condition affecting the retina. Two years ago he came in for a follow-up appointment where he learned that he had the opportunity to be one of the very first to ever be enrolled in a gene therapy trial for his rare eye disease. Mason gives credit to the research scientists at the Retina Foundation for gifting him with the hope that a cure for X-linked retinoschisis may be on the horizon. Click here to read more of Mason’s incredible story on www.dallasnews.com.

Related Articles
Video Game Software Patented for Age-Related Macular Degeneration Research Recently@Retina Newsletter January 2023 The Retina Foundation Hosts Eye On Innovation, The Series, to Discuss Transforming Dallas Health – The Legacy of T. Boone Pickens. The Phyllis G. & William B. Snyder Legacy Society Recently@Retina Newsletter August 2024